Trial Profile

Phase 1 Study to Evaluate the Safety and Efficacy of TILs Transduced With IL-7 (ADP-TILIL7) in Patients With Locally Advanced or Metastatic Melanoma

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADP-TILIL7 (Primary) ; Interleukin-2 (Primary) ; Cyclophosphamide; Fludarabine
Indications Malignant melanoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Adaptimmune

Most Recent Events

14 Mar 2025 Planned End Date changed from 1 Apr 2027 to 1 Apr 2028.
14 Mar 2025 Planned primary completion date changed from 1 Mar 2026 to 1 Mar 2027.
14 Mar 2025 Planned initiation date changed from 1 Mar 2024 to 1 May 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com